Rayner
Rahul Dutta, PhD, has extensive work experience in the field of optical design and research. Rahul currently holds the position of Optical Design Engineer at Rayner since October 2020. Prior to this, they worked as an Optical Scientist at Johnson & Johnson Vision from October 2018 to September 2020.
Rahul also served as a Postdoctoral Researcher at Universidad de Murcia from August 2017 to September 2018. Earlier in their career, they held the roles of Project Researcher and Doctoral Researcher at the University of Eastern Finland, where they conducted research on various projects from July 2012 to November 2016. Additionally, they worked as a Summer Trainee at Oplatek Group Oy in August 2013.
Furthermore, Rahul has contributed as a Research Assistant at both the University of Eastern Finland and Tampere University of Technology from January 2012 to May 2012, and at the University of Eastern Finland from July 2011 to October 2011.
Overall, Rahul Dutta, PhD has gained valuable experience and expertise in optical design, research, and project management throughout their career.
Rahul Dutta, PhD, obtained their Doctor of Philosophy (Ph.D.) degree in Photonics from the University of Eastern Finland between 2012 and 2016. Prior to that, they pursued a Master of Science (M.Sc.) degree in Photonics at the same university from 2010 to 2012. Rahul's educational journey began with a Bachelor of Technology (B.Tech.) in Optoelectronics from the University of Calcutta, which they completed between 2007 and 2010. Before entering their undergraduate studies, they obtained a Bachelor of Science (B.Sc.) degree in Physics, also from the University of Calcutta, from 2004 to 2007.
This person is not in any offices
Rayner
5 followers
Rayner designs and manufactures intraocular lenses and proprietary injection devices for use in cataract surgery. When Sir Harold Ridley designed the world’s first IOL in 1949, he chose Rayner to manufacture this ground-breaking invention.With more than 65 years of continuous growth and experience, we remain at the forefront of innovation. Weare focused on providing the best IOLs for clinicians and patients and are driven by science to improve patient outcomes and safety.Primary IOLs Our FDA-approved C-flex aspheric (aberration-neutral) monofocal IOL, as well as our toric and multifocal IOL families are now complemented by the RayOne fully preloaded monofocal IOL injection system. Supplementary IOLsDesigned to be implanted in the ciliary sulcus, Rayner Sulcoflex Pseudophakic Supplementary IOLs are available as aspheric, toric, multifocal and multifocal lenses, and offer a reversible solution for correcting residual post-operative refractive errors following the implantation of a conventional IOL in the capsular bag.OVDsOur Ophteis range offers a full spectrum of OVDs from dispersive to cohesive, enabling surgeons to select the OVD best suited to each specific cataract procedure. Ophteis FR Pro with sorbitol -- designed to deliver a new level of corneal endothelial protection from phaco induced trauma -- is the flagship product of Rayner’s ‘Ophteis’ OVD suite. PharmaceuticalsAlthough the intraocular lens plays a leading role in the visual outcomes of cataract and refractive surgery, the pharmaceuticals that manage the tear film and inflammation are critical to the end result. For that reason, Rayner recently acquired the business of Moorfields Pharmaceuticals. The acquisition will enable us to offer an even wider range of ophthalmic tools that aid and streamline the surgical process whilst remaining focused on the visual outcome for the patient.Rayner markets its IOL portfolio and related products worldwide through a network of distributors in over 80 countries with direct markets in UK, Germany & Austria, the United States of America, Italy and Spain. We have the world’s longest commercial history of IOL design and manufacturing and have worked with cataract surgeons for longer than anyone else.In 2016, Rayner transferred its global headquarters to a brand new state of the art manufacturing plant, which has dramatically increased the company’s production capacity.